Published Apr 28, 2026

Introduction

Poor aqueous solubility is one of the leading causes of failure in oral drug development. In fact, ~40% of marketed drugs and up to 70–90% of pipeline compounds exhibit poor water solubility, making dissolution the rate-limiting step for absorption¹.

Amorphous Solid Dispersion (ASD) has emerged as one of the most effective formulation strategies to overcome this challenge—enabling faster dissolution, improved bioavailability, and successful clinical progression.

As drug molecules become increasingly complex, ASD is no longer just a formulation option—it is a critical developability strategy.

What Is ASD?

ASD is a formulation approach in which drug molecules are molecularly dispersed within a polymer matrix in a non-crystalline (amorphous) state. Unlike crystalline materials, where molecules are arranged in a highly ordered lattice, amorphous systems exist in a higher-energy, disordered structure. This eliminates the crystal lattice barrier and allows the drug to dissolve more rapidly and reach higher apparent solubility².

Why ASD Matters in Drug Development

ASD directly addresses one of the most persistent challenges in pharmaceutical development:

• ~40% of marketed drugs are poorly water-soluble.

• 70–90% of pipeline compounds fall into BCS Class II or IV

• Poor dissolution is a leading cause of clinical failure.

By removing the lattice energy barrier and enabling supersaturation, ASD allows poorly soluble compounds to achieve sufficient exposure for therapeutic effect.

How ASD Works

From Crystalline to Amorphous

In crystalline APIs, molecules are tightly packed in a repeating lattice. Before dissolution can occur, the system must overcome this lattice energy. ASD bypasses this step by stabilizing the drug in an amorphous state, where no lattice exists - resulting in:

• Faster dissolution

• Better wetting

• Higher apparent solubility

• Improved absorption potential

The Role of Polymer Carriers

Polymers are essential to ASD performance and stability. They serve multiple functions:

• Stabilization - Prevent recrystallization by reducing molecular mobility.

• Supersaturation maintenance - Sustain drug concentration in solution.

• Solubilization - Improve wetting and dissolution behavior.

• Processability - Enable manufacturing via spray drying or hot-melt extrusion.

Common polymers include HPMC-AS, PVP/VA, Soluplus®, HPMC, Eudragit®, etc., each selected based on API compatibility and formulation goals.

Manufacturing Technologies for ASD

Spray Drying (SD)

Spray drying involves atomizing a drug-polymer-excipient solution into a heated chamber, where rapid solvent evaporation traps the API in its amorphous form within the polymer matrix.

Key advantages:

• Suitable for temperature-sensitive compounds

• Less API quantity is needed compared with other ASD technologies.

• Produces particles with controlled morphology and particle size distribution.

• Continuous process

• Scalable from early development to commercial production

Hot-Melt Extrusion (HME)

HME processes drug-polymer blends under heat and mechanical shear, forming a homogeneous amorphous dispersion (e.g., glass) without solvents.

Key advantages:

• Solvent-free process with lower cost than spray drying.

• Continuous process with the implementation of process analytics technology (PAT)

• High throughput and robustness

• Ideal for thermally stable APIs with low Tm and Tg

When Is ASD the Right Formulation Strategy?

ASD as a Widely Adopted Industry Strategy

ASD has become one of the most widely used enabling technologies in modern drug development, with numerous commercial products successfully utilizing ASD-based formulations³.

This broad adoption reflects its effectiveness in addressing solubility-driven bioavailability challenges. ASD is particularly effective under the following conditions:

When Should You NOT Use ASD?

While powerful, ASD is not universally applicable. ASD may not be ideal when:

• The API already has sufficient solubility, especially in the intestine.

• The compound is highly thermally unstable (limits HME use)

• Very high doses (>500 mg) make oral solid formulations impractical.

Early developability assessment is critical to selecting the right strategy.

Key Considerations for Successful ASD Development

1. Polymer Selection
The most critical decision in ASD development. Polymer choice determines stability, drug loading capacity, and dissolution performance.

2. Drug Loading
Higher drug loading increases the risk of phase separation or recrystallization. Optimal loading must balance performance and stability and is determined by drug-polymer compatibility.

3. Physical Stability
ASD systems are kinetically stable but thermodynamically metastable and require careful evaluation using:

• XRPD (recrystallization detection)

• DSC (glass transition temperature, phase seperation)

• Accelerated stability studies

4. In Vitro Performance
Dissolution testing in biorelevant media (SGF, FaSSIF, FeSSIF) ensures:

• Supersaturation maintenance

• Predictive in vivo performance

ASD vs Conventional Formulation Approaches

ASD Development Capabilities at Crystal Pharmatech

Successful ASD development requires more than selecting a formulation—it demands a deep integration of solid-state science, formulation strategy, and scalable manufacturing. At Crystal Pharmatech, ASD development is embedded within a Mol2Med™ “first-time-right” framework, enabling seamless progression from early feasibility to clinical manufacturing.

Integrated ASD Development Workflow

Our end-to-end approach connects:

• Developability assessment

• Solid-state characterization

• ASD screening & formulation development

• Process development (spray drying / HME)

• GMP clinical manufacturing

ASD Development Timeline: What to Expect

Compared to conventional formulation approaches (~6 months), ASD formulation packages typically require ~7.5 months, reflecting additional ASD formulation screening and optimization work. However, this modest upfront investment significantly reduces downstream risk and improves the likelihood of clinical success.

Advanced Technology Platforms

• Spray drying and particle engineering.

• Hot-melt extrusion (continuous manufacturing)

• Full analytical and characterization support

• Scale up from lab to pilot and commercial scales

One-Stop Mol2Med™ Advantage

This integrated approach enables:

• Faster transition from API to oral dosage form

• Reduced CMC risk

• Improved clinical success probability.

With a proven track record of ~ 80 ASD programs, including 26 GMP-stage projects, Crystal Pharmatech combines scientific expertise with real-world execution experience—ensuring that formulation strategies are not only theoretically sound, but also scalable, manufacturable, and clinically viable.

Conclusion

Amorphous Solid Dispersion has become a cornerstone technology in modern drug development. By enabling oral delivery of poorly soluble compounds, ASD significantly improves the likelihood of clinical success. However, its success depends on sound material science, early evaluation, appropriate polymer selection, and integrated development strategy.

Frequently Asked Questions (FAQ)

• What is amorphous solid dispersion in simple terms?
  ASD is a formulation technique where drug molecules are dispersed at the molecular level in a polymer, eliminating crystal structure and improving dissolution.

• Why are so many drugs poorly soluble?
  Modern drug molecules are often larger and more lipophilic, improving target binding and absorption but reducing solubility in aqueous environments⁴.

• What does BCS Class II mean?
  BCS Class II drugs have low solubility but high permeability, making solubility or dissolution speed the limiting step for absorption.

• How do you know if ASD will work for a specific drug?
  Feasibility studies evaluate polymer compatibility, drug loading, stability, and kinetic solubility behavior.

• What is the difference between ASD and crystalline formulation?
  ASD eliminates lattice energy barriers and improves solubility, while crystalline forms are more stable but dissolve slowly with lower solubility.

• What technologies are used to manufacture ASD?
  The two primary methods are spray drying (SD) and hot-melt extrusion (HME).

References

1. Bhujbal et al., Amorphous Solid Dispersion: A Review, Int J Pharm, 2021

2. Hancock & Zografi, Characteristics and Significance of the Amorphous State, J Pharm Sci

3. Jermain et al., Amorphous Solid Dispersions: A Review, Mol Pharmaceutics

4. Lipinski et al., Experimental and Computational Approaches to Estimate Solubility and Permeability, Adv Drug Deliv Rev